This purified, recombinant, mouse monoclonal antibody recognizes BRD7 in human samples.

Recombinant antibody characteristics include:
• Validation in immunoprecipitation
• Superior lot-to-lot consistency
• Extremely high specificity and sensitivity
• Recombinant mouse monoclonal antibody
• Specific for BRD7

BRD7 acts both as coactivator and as corepressor. For example, it activates the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. In addition, it is required for TP53-mediated cell-cycle arrest in response to oncogene activation. BRD7 promotes acetylation of TP53 at Lys-382, and thereby promotes efficient recruitment of TP53 to target promoters, thereby inhibiting cell cycle progression from G1 to S phase.

Exceptional Consistency Saves You Time and Money
Recombinant antibodies are produced by transfection of mammalian cells with heavy and light chain antibody cDNAs. This provides you with the highest consistency between lots, eliminating the need to revalidate your assays for each lot.

High Specificity Means More Reliable Data
The recombinant technology employed in manufacture of the antibody assures greatest degree of reliability. Staining of nonspecific proteins is virtually eliminated while very high sensitivity is achieved. Life Technologies has validated this antibody in immunoprecipitation.

High Sensitivity Lets You Detect Low Levels of Target Protein
Recombinant antibodies demonstrate much higher sensitivity than ordinary antibodies. Proteins expressed in low levels can be detected with high specificity allowing you to use less of your precious samples than with ordinary antibodies.

Recombinant mouse IgG-Use Like Any Other IgG Antibody
As with traditional IgG antibodies, gel electrophoresis of recombinant antibodies produces a 150 kDa band under non-reducing conditions and 50 kDa and 25 kDa bands under reducing conditions.

Related Links:
Learn more about the superior performance of ABfinity™recombinant monoclonal antibodies.
See Life Technologies' full line of ABfinity™recombinant monoclonal antibodies.